4Q Revenue of $1.36 billion; 1% reported growth; -9% organic growth 4Q GAAP EPS from continuing operations of $1.41; Adjusted EPS of $2.56 Initiates First Quarter and Full Year 2022 Guidance WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 1, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for... Read more
MENLO PARK, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022, at 4:30 pm Eastern Time. The call will be webcast live and may be accessed at Pacific... Read more
Basel, 1 February 2022 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that William Pao (1967), M.D., Ph.D., and Head of Roche Pharma Research and Early Development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the United States, effective 18 March 2022. Johannes (Hans) Clevers (1957), M.D., Ph.D.,... Read more
FRANKLIN LAKES, N.J., Feb. 1, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring... Read more
RYE BROOK, N.Y.–(BUSINESS WIRE)–Jan. 31, 2022– Global water technology leader, Xylem (NYSE:XYL), today announced the appointment of Mark Morelli to the Company’s Board of Directors, effective February 3, 2022. Mr. Morelli currently serves as President and CEO of Vontier Corporation, the $3B global industrial technology company focused on smarter mobility. He brings nearly two decades... Read more
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient need Basel, 31 January 2022 – Roche (SIX: RO, ROG; OTCQX:... Read more